UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.

@article{Ando2007UGT1AI6AU,
  title={UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.},
  author={Yuichi Ando and Ken-Ichi Fujita and Yasutsuna Sasaki and Yoshinori Hasegawa},
  journal={Current opinion in molecular therapeutics},
  year={2007},
  volume={9 3},
  pages={258-62}
}
Genetic polymorphisms of uridine 5'-diphospho-glucuronosyl-transferase (UGT)1A1, a crucial drug-metabolizing enzyme of the anticancer drug irinotecan, are essential determinants of individual variation in susceptibility to irinotecan-related toxicity. The FDA has revised the package insert of irinotecan in order to warn of the association between toxicity and UGTIA1*28, a variant sequence in a promoter region of the UGTIA1 gene. Unlike UGT1A1*28, UGT1AI*6 and UGTIA1*27 polymorphisms are found… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…